BioNTech SE (BNTX) Income towards Parent Company (2018 - 2025)
BioNTech SE's (BNTX) quarterly Income towards Parent Company came in at -$174.4 million in Q4 2025, down 162.88% year-on-year from $277.3 million in Q4 2024, and down 290.98% quarter-over-quarter from $91.3 million in Q3 2025.
BioNTech SE (BNTX) Income towards Parent Company (2018 - 2025) Analysis & Trends
BioNTech SE has disclosed Income towards Parent Company across 8 years of filings, most recently posting -$174.4 million for Q4 2025.
- Income towards Parent Company for Q4 2025 came in at -$174.4 million, down 162.88% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.1 billion (down 32.16% YoY), and the FY2025 annual result was -$1.1 billion, down 47.92% from the prior year.
- Income towards Parent Company came in at -$174.4 million for Q4 2025 at BioNTech SE, down from $91.3 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $4.2 billion in Q1 2022 to a low of -$865.6 million in Q2 2024.
- The 5-year median for Income towards Parent Company is $298.8 million (2024), against an average of $1.0 billion.
- Across the five-year window, Income towards Parent Company surged 114544050.96% in 2022 and plunged 317.5% in 2024, its largest moves.
- BioNTech SE's Income towards Parent Company stood at $3622.0 in 2021, then soared by 114544050.96% to $4.1 billion in 2022, then sank by 88.13% to $492.7 million in 2023, then slumped by 43.72% to $277.3 million in 2024, then plunged by 162.88% to -$174.4 million in 2025.
- The last three Income towards Parent Company figures came in at -$174.4 million (Q4 2025), $91.3 million (Q3 2025), and -$474.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | BioNTech SE | 27.38 Bn | 10.07 Bn | 668.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -174.37 Mn |
| Sep 30, 2025 | 91.30 Mn |
| Jun 30, 2025 | -474.06 Mn |
| Mar 31, 2025 | -499.65 Mn |
| Dec 31, 2024 | 277.30 Mn |
| Sep 30, 2024 | 131.02 Mn |
| Jun 30, 2024 | -865.60 Mn |
| Mar 31, 2024 | -342.31 Mn |
| Dec 31, 2023 | 492.67 Mn |
| Sep 30, 2023 | 320.26 Mn |
| Jun 30, 2023 | -207.33 Mn |
| Mar 31, 2023 | 539.03 Mn |
| Dec 31, 2022 | 4.15 Bn |
| Sep 30, 2022 | 3.13 Bn |
| Jun 30, 2022 | 1.78 Bn |
| Mar 31, 2022 | 4.15 Bn |
| Dec 31, 2021 | 3,622.04 |
| Sep 30, 2021 | 1.72 Bn |
| Jun 30, 2021 | 3.36 Bn |
| Mar 31, 2021 | 2.60 Bn |